Overview

Upfront Treatment With Chemotherapy and Bevacizumab in Advanced Ovarian Cancer

Status:
Not yet recruiting
Trial end date:
2022-09-01
Target enrollment:
0
Participant gender:
Female
Summary
Our study aims at assessment of response, survival and toxicity of frontline treatment with chemotherapy and Bevacizumab in patients having advanced epithelial ovarian cancer.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Nada Hassan Salah
Collaborator:
Assiut University
Treatments:
Bevacizumab
Criteria
Inclusion Criteria:

- Female patients diagnosed with advanced ovarian cancer by biopsy

- Age more than 18 years old

- Routine labs are within normal values ( CBC, renal function tests , liver function
tests )

- Performance score 0-2

- FIGO stage II-IV

- Not having any contraindication to bevacizumab as : uncontrolled hypertension ,
bleeding tendency , ischaemic events

- Chemotherapy naïve.

- Informed consent

Exclusion Criteria:

- patients previously received chemotherapy or radiotherapy to any part of the abdomen
or pelvis

- patients with uncontrolled infection

- patients with clinically significant cardiovascular disease

- patients with active bleeding or conditions associated with high risk of bleeding

- patients with history of CNS disease